Scott Isaacs
@scottisaacsmd
President-Elect @theaace, endocrinologist, obesity medicine, #MASLD, Emory Med School adjunct faculty. Posts are my own.
ID:213754594
http://www.atlantaendocrine.com 09-11-2010 18:24:54
5,7K Tweets
12,7K Followers
2,0K Following
Follow People
The approval of #resmetirom for #MASH is a major advance in the treatment of steatotic liver disease.
Jeffrey V. Lazarus Zobair Younossi
www-nature-com.proxy.library.emory.edu/articles/s4159…
Point/Counterpoint: SGLT-2 Inhibitor Use. This article describes the risks associated with the use of SGLT2i for the management of inpatient hyperglycemia: endocrinepractice.org/article/S1530-… #endotwitter Elsevier Endocrinology & Diabetes Vin Tangpricha, MD, PhD
Love to see Scott Isaacs discussing importance of #exercise (and all other aspects of leading a healthy lifestyle) in managing metabolic disease here at the #MidwestMetabolicClinicalSymposium
This meta-analysis examined the effectiveness and safety of #tirzepatide in treating overweight and obesity compared with other weight loss drugs and GLP-1 receptor agonists.
onlinelibrary.wiley.com/doi/epdf/10.10…